Press Releases

CRANBURY, N.J., Feb. 13, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2014.  “We achieved a significant clinical and corporate milestone by advancing bremelanotide […]

CRANBURY, N.J., Feb. 9, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2015 operating results on Friday, February 13, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13,

CRANBURY, N.J., Feb. 6, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.

Triggers euro 2.5 Million (~$3 Million) Milestone Payment from Gedeon Richter CRANBURY, N.J., Dec. 29, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program. 

CRANBURY, N.J. and FARMINGTON, Conn., Dec. 24, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has closed on a private placement of 2,050,000 shares of its common stock and

CRANBURY, N.J., Nov. 18, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2014.  Recent Highlights Bremelanotide development for Female Sexual Dysfunction (FSD): €7.5M ($9.8M)

CRANBURY, N.J., Nov. 13, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2015 operating results on Tuesday, November 18, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 18,

RED BANK, N.J., Nov. 4, 2014 /PRNewswire/ — Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire that is accompanied by distress

CRANBURY, N.J., Oct. 8, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting today at the 13th Annual BIO Investor Forum at 11:00 a.m. Pacific Time. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum will take place October 7-8 at The Palace Hotel in San Francisco,

CRANBURY, N.J., Sept. 9, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2014.  Fiscal Year Ended June 30, 2014 and Recent